Prognostic Impact of IL17 A Gene Polymorphismson Egyptian Patients with Multiple Myeloma

Document Type : Research Articles


1 Hematology Unit, Department of Clinical Pathology, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt.

2 Clinical Hematology Unit, Department of Internal Medicine, Oncology Center, Mansoura University, Mansoura, Egypt.

3 Departement of Oncology, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt.

4 Departement of Molecular Biology, Oncology Center, Mansoura University, Mansoura, Egypt.

5 Department of Public Health and Community Medicine, Faculty of Medicine, Mansoura, Egypt.


Introduction: Multiple myeloma (MM) is a B-cell lymphoproliferative disease in which the bone marrow microenvironment plays an important role in pathogenesis. The T helper (Th-17) cell plays an important role in the development of cancer by releasing pro-inflammatory cytokines such as IL-17A and IL-17F. Th-17 cells have been studied in a variety of solid tumors, as well as few hematological malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, and monoclonal gammopathy of unknown significance. Aim: Our study aimed to assess the association between IL-17A polymorphism and MM risk and other MM characteristics in Egyptian patients. Patients & Methods: a prospective study involving 77 patients with MM (mean age 54.6 years; males 53.2%; females 46.8%) and a healthy control group of same age and gender. It was performed at the Mansoura University Oncology Center (OCMU). The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach was used to detect IL17A 197 G/A (rs2275913) genotypes in genomic DNA from MM patients and healthy controls. Results: The IL-17A polymorphism may not be associated to myeloma predilection in the Egyptians as a whole. There was also no significant correlation in statistical study between gender and the IL-17A polymorphism. (p 0.14), a number of clinical and laboratory characteristics, including hypercalcemia (p 0.28), hypoalbuminemia (p 0.49), renal impairment (p 0.13), high LDH (p 0.62), osteolytic bone lesions (p 0.26), and pathological fracture (p 0.96), are also present. Nevertheless, no statistically significant difference in the OS of MM patients was detected for the IL-17A polymorphism (p 0.83). Conclusion: Our research demonstrated that IL-17A polymorphism may not be linked to multiple myeloma susceptibility in our population and did not influence its different clinical and laboratory features. IL-17A polymorphism had no effect on OS in MM patients.


Main Subjects